Blood eosinophils in COPD: are biologics for everyone?
Background: Type 2 (T2) biologics represent a promising treatment option for chronic obstructive pulmonary disease (COPD) patients with eosinophilic inflammation. Objectives: To evaluate the prevalence of stable COPD patients who may be eligible for T2 biologics. Design: Real-world, retrospective, monocentric study in...